First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC
Crossref DOI link: https://doi.org/10.1038/s41571-023-00809-3
Published Online: 2023-07-28
Published Print: 2023-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Romero, Diana
Text and Data Mining valid from 2023-07-28
Version of Record valid from 2023-07-28
Article History
First Online: 28 July 2023